Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity

Artur Plonowski, Jozsef L. Varga, Andrew V Schally, Magdalena Krupa, Kate Groot, Gabor Halmos

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Vasoactive intestinal peptide (VIP) stimulates the proliferation and invasiveness of malignant prostatic cells. Receptors for VIP and the closely related growth hormone-releasing hormone (GH-RH) show considerable homology and are found in prostatic and other carcinomas. Among various analogs of GH-RH synthesized, JV-1-52 is a non-selective VIP/GH-RH antagonist, whereas JV-1-53 is a VIP antagonist devoid of GH-RH antagonistic effect. In our study, nude mice bearing PC-3 human androgen-independent prostate carcinomas were treated with JV-1-52 or JV-1-53 (20 μg/day, s.c.) for 28 days. Both antagonists produced a similar reduction in tumor volume (62-67%, p < 0.01) and tumor weight (59-62%; p < 0.05) vs. controls and extended tumor doubling-time from 9.1 to about 16 days (p < 0.05). To investigate the mechanisms involved, in another study we compared the effects of JV-1-53 with those of somatostatin analog RC-160. VIP antagonist JV-1-53 reduced tumor weight by 67% (p < 0.01) and suppressed the expression of mRNA for c-fos and c-jun oncogenes by about 34% (p < 0.05), without affecting serum levels of insulin-like growth factor-I (IGF-I). In conRC-160 (50 μg/day) reduced serum IGF-I by 19% (p < 0.05), but did not significantly decrease tumor weight, mRNA for VIP and high affinity receptors for VIP were detected on PC-3 tumors. Our results suggest that VIP/GH-RH antagonists can inhibit the growth of androgen-independent prostate cancer by abrogating the autocrine/paracrine mitogenic stimuli of VIP. The ability of GH-RH antagonists to block tumoral VIP receptors, in addition to GH-RH receptors, could be potentially beneficial for prostate cancer therapy.

Original languageEnglish
Pages (from-to)624-629
Number of pages6
JournalInternational Journal of Cancer
Volume98
Issue number4
DOIs
StatePublished - Apr 1 2002
Externally publishedYes

Fingerprint

Growth Hormone-Releasing Hormone
Vasoactive Intestinal Peptide
Prostatic Neoplasms
Vasoactive Intestinal Peptide Receptors
Tumor Burden
Hormone Antagonists
Gastrointestinal Hormones
Peptide Hormones
Insulin-Like Growth Factor I
Androgens
jun Genes
Carcinoma
Messenger RNA
Somatostatin
Serum
Nude Mice
Prostate
Neoplasms
JV 1-53
Growth

Keywords

  • Androgen-independent prostate cancer
  • Antagonist of vasoactive intestinal peptide
  • Growth hormone-releasing hormone

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity. / Plonowski, Artur; Varga, Jozsef L.; Schally, Andrew V; Krupa, Magdalena; Groot, Kate; Halmos, Gabor.

In: International Journal of Cancer, Vol. 98, No. 4, 01.04.2002, p. 624-629.

Research output: Contribution to journalArticle

@article{5e5db05d8b154c4cb3f297a4acda4d39,
title = "Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity",
abstract = "Vasoactive intestinal peptide (VIP) stimulates the proliferation and invasiveness of malignant prostatic cells. Receptors for VIP and the closely related growth hormone-releasing hormone (GH-RH) show considerable homology and are found in prostatic and other carcinomas. Among various analogs of GH-RH synthesized, JV-1-52 is a non-selective VIP/GH-RH antagonist, whereas JV-1-53 is a VIP antagonist devoid of GH-RH antagonistic effect. In our study, nude mice bearing PC-3 human androgen-independent prostate carcinomas were treated with JV-1-52 or JV-1-53 (20 μg/day, s.c.) for 28 days. Both antagonists produced a similar reduction in tumor volume (62-67{\%}, p < 0.01) and tumor weight (59-62{\%}; p < 0.05) vs. controls and extended tumor doubling-time from 9.1 to about 16 days (p < 0.05). To investigate the mechanisms involved, in another study we compared the effects of JV-1-53 with those of somatostatin analog RC-160. VIP antagonist JV-1-53 reduced tumor weight by 67{\%} (p < 0.01) and suppressed the expression of mRNA for c-fos and c-jun oncogenes by about 34{\%} (p < 0.05), without affecting serum levels of insulin-like growth factor-I (IGF-I). In conRC-160 (50 μg/day) reduced serum IGF-I by 19{\%} (p < 0.05), but did not significantly decrease tumor weight, mRNA for VIP and high affinity receptors for VIP were detected on PC-3 tumors. Our results suggest that VIP/GH-RH antagonists can inhibit the growth of androgen-independent prostate cancer by abrogating the autocrine/paracrine mitogenic stimuli of VIP. The ability of GH-RH antagonists to block tumoral VIP receptors, in addition to GH-RH receptors, could be potentially beneficial for prostate cancer therapy.",
keywords = "Androgen-independent prostate cancer, Antagonist of vasoactive intestinal peptide, Growth hormone-releasing hormone",
author = "Artur Plonowski and Varga, {Jozsef L.} and Schally, {Andrew V} and Magdalena Krupa and Kate Groot and Gabor Halmos",
year = "2002",
month = "4",
day = "1",
doi = "10.1002/ijc.10221",
language = "English",
volume = "98",
pages = "624--629",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity

AU - Plonowski, Artur

AU - Varga, Jozsef L.

AU - Schally, Andrew V

AU - Krupa, Magdalena

AU - Groot, Kate

AU - Halmos, Gabor

PY - 2002/4/1

Y1 - 2002/4/1

N2 - Vasoactive intestinal peptide (VIP) stimulates the proliferation and invasiveness of malignant prostatic cells. Receptors for VIP and the closely related growth hormone-releasing hormone (GH-RH) show considerable homology and are found in prostatic and other carcinomas. Among various analogs of GH-RH synthesized, JV-1-52 is a non-selective VIP/GH-RH antagonist, whereas JV-1-53 is a VIP antagonist devoid of GH-RH antagonistic effect. In our study, nude mice bearing PC-3 human androgen-independent prostate carcinomas were treated with JV-1-52 or JV-1-53 (20 μg/day, s.c.) for 28 days. Both antagonists produced a similar reduction in tumor volume (62-67%, p < 0.01) and tumor weight (59-62%; p < 0.05) vs. controls and extended tumor doubling-time from 9.1 to about 16 days (p < 0.05). To investigate the mechanisms involved, in another study we compared the effects of JV-1-53 with those of somatostatin analog RC-160. VIP antagonist JV-1-53 reduced tumor weight by 67% (p < 0.01) and suppressed the expression of mRNA for c-fos and c-jun oncogenes by about 34% (p < 0.05), without affecting serum levels of insulin-like growth factor-I (IGF-I). In conRC-160 (50 μg/day) reduced serum IGF-I by 19% (p < 0.05), but did not significantly decrease tumor weight, mRNA for VIP and high affinity receptors for VIP were detected on PC-3 tumors. Our results suggest that VIP/GH-RH antagonists can inhibit the growth of androgen-independent prostate cancer by abrogating the autocrine/paracrine mitogenic stimuli of VIP. The ability of GH-RH antagonists to block tumoral VIP receptors, in addition to GH-RH receptors, could be potentially beneficial for prostate cancer therapy.

AB - Vasoactive intestinal peptide (VIP) stimulates the proliferation and invasiveness of malignant prostatic cells. Receptors for VIP and the closely related growth hormone-releasing hormone (GH-RH) show considerable homology and are found in prostatic and other carcinomas. Among various analogs of GH-RH synthesized, JV-1-52 is a non-selective VIP/GH-RH antagonist, whereas JV-1-53 is a VIP antagonist devoid of GH-RH antagonistic effect. In our study, nude mice bearing PC-3 human androgen-independent prostate carcinomas were treated with JV-1-52 or JV-1-53 (20 μg/day, s.c.) for 28 days. Both antagonists produced a similar reduction in tumor volume (62-67%, p < 0.01) and tumor weight (59-62%; p < 0.05) vs. controls and extended tumor doubling-time from 9.1 to about 16 days (p < 0.05). To investigate the mechanisms involved, in another study we compared the effects of JV-1-53 with those of somatostatin analog RC-160. VIP antagonist JV-1-53 reduced tumor weight by 67% (p < 0.01) and suppressed the expression of mRNA for c-fos and c-jun oncogenes by about 34% (p < 0.05), without affecting serum levels of insulin-like growth factor-I (IGF-I). In conRC-160 (50 μg/day) reduced serum IGF-I by 19% (p < 0.05), but did not significantly decrease tumor weight, mRNA for VIP and high affinity receptors for VIP were detected on PC-3 tumors. Our results suggest that VIP/GH-RH antagonists can inhibit the growth of androgen-independent prostate cancer by abrogating the autocrine/paracrine mitogenic stimuli of VIP. The ability of GH-RH antagonists to block tumoral VIP receptors, in addition to GH-RH receptors, could be potentially beneficial for prostate cancer therapy.

KW - Androgen-independent prostate cancer

KW - Antagonist of vasoactive intestinal peptide

KW - Growth hormone-releasing hormone

UR - http://www.scopus.com/inward/record.url?scp=0036533618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036533618&partnerID=8YFLogxK

U2 - 10.1002/ijc.10221

DO - 10.1002/ijc.10221

M3 - Article

C2 - 11920625

AN - SCOPUS:0036533618

VL - 98

SP - 624

EP - 629

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -